---
title: "Merck presents first Phase 3 INTerpath-001 data on intismeran plus Keytruda in resected melanoma at ESMO 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301697764.md"
description: "Merck presented first Phase 3 INTerpath-001 data on intismeran plus Keytruda for resected melanoma at ESMO 2026. The company highlighted three late-breaking symposia covering melanoma and endometrial cancer studies, including sacituzumab tirumotecan and Keytruda monotherapy in dMMR endometrial cancer. These disclosures aim to drive future label expansions and pipeline value."
datetime: "2026-10-13T10:46:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301697764.md)
  - [en](https://longbridge.com/en/news/301697764.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301697764.md)
generator: "portal-rs"
---

# Merck presents first Phase 3 INTerpath-001 data on intismeran plus Keytruda in resected melanoma at ESMO 2026

-   Merck flagged first-time pivotal Phase 3 data from its oncology pipeline for presentation at ESMO 2026 in Madrid. \* Results have not been presented yet; three late-breaking Presidential Symposia will feature melanoma and endometrial cancer studies. \* Key readouts cover intismeran autogene with Keytruda in resected melanoma, sacituzumab tirumotecan in post-treatment endometrial cancer. \* A separate Phase 3 trial will present Keytruda monotherapy as an initial treatment option in dMMR advanced or recurrent endometrial cancer. \* Merck positioned the set of Phase 3 disclosures as a potential driver of future label expansion and pipeline value in oncology. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261013301331) on October 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Merck Says Intismeran Plus Keytruda Significantly Reduced Risk Of Recurrence Or Death By 42%](https://longbridge.com/en/news/302764536.md)
- [MSD’s Keytruda and Padcev combination receives EC approval](https://longbridge.com/en/news/302677633.md)
- [Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine](https://longbridge.com/en/news/305169520.md)
- [Tesla Is Squeezing More Money Out Of The Cybertruck Before It Dies](https://longbridge.com/en/news/305193173.md)
- [Has Nvidia flown too close to the sun? One analyst warns of major scrutiny ahead.](https://longbridge.com/en/news/305198746.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**